Oral Micronized Progesterone Overdose and Accidental Excess Dose

What Is Oral Micronized Progesterone and How Does It Work?

Oral micronized progesterone (brand name Prometrium, plus generics) is bioidentical progesterone suspended in peanut oil inside a soft-gelatin capsule. The micronization process reduces particle size to below 10 microns, which dramatically increases intestinal absorption compared to unmicronized powder. Without micronization, oral bioavailability of progesterone is under 10%. The FDA approved Prometrium in 1998 specifically because micronization solved that absorption problem.

Receptor-Level Mechanism

Progesterone acts primarily on two nuclear receptor subtypes, PRA and PRB, which are expressed in the uterus, breast, brain, cardiovascular tissue, and bone. Binding these receptors changes gene transcription in a tissue-specific way. In the endometrium, progesterone receptor activation converts proliferative endometrium to secretory endometrium, opposing the mitogenic effect of estrogen. This is why progesterone is co-prescribed in any woman with an intact uterus receiving systemic estrogen therapy, as confirmed by the 2022 Menopause Society (NAMS) hormone therapy position statement.

The Neurosteroid Pathway That Drives Overdose Risk

After oral ingestion, progesterone undergoes extensive first-pass hepatic metabolism. Two key metabolites form: 5-alpha-pregnanolone and allopregnanolone (3-alpha, 5-alpha-tetrahydroprogesterone). Allopregnanolone is a potent positive allosteric modulator of GABA-A receptors, the same target as benzodiazepines and alcohol. This is not a side effect unique to overdose. Even at standard 200 mg doses, plasma allopregnanolone concentrations reach levels sufficient to cause sedation, which is why Prometrium is dosed at bedtime and why somnolence appears in roughly 30% of patients in clinical trials. At supratherapeutic doses, this GABA-A potentiation becomes the dominant clinical risk. Bäckström et al. Documented the progesterone-to-allopregnanolone conversion and its CNS effects in a widely cited pharmacology review on PubMed.

Endometrial Protection: The Clinical Reason the Drug Exists

The PEPI Trial (N=875, JAMA 1995) compared four hormone therapy regimens in postmenopausal women over 3 years. Oral micronized progesterone 200 mg per day (cyclic) produced endometrial protection equivalent to medroxyprogesterone acetate (MPA) while delivering a significantly better HDL-cholesterol profile than MPA. The trial found that only 1% of women on the micronized progesterone arm developed simple endometrial hyperplasia, compared to 62% on unopposed estrogen (PEPI Trial, JAMA 1995). That single statistic is the foundational clinical justification for the drug's continued use.

Pharmacokinetics: What the Body Does to Each Capsule

Understanding overdose risk requires knowing where the drug goes and how fast.

Absorption and Peak Concentration

A single 200 mg oral dose in postmenopausal women produces a mean peak serum progesterone concentration (Cmax) of approximately 17.8 ng/mL, reached at around 3 hours post-dose (Tmax). The Prometrium prescribing information filed with FDA reports this from crossover pharmacokinetic studies. The same label notes that food increases bioavailability 3-fold compared to fasting, meaning a patient who accidentally doubles their dose after a meal faces higher peak exposure than one who doubles it on an empty stomach.

Half-Life and Duration

The elimination half-life of progesterone itself is relatively short, approximately 5 to 20 hours depending on the study and individual metabolic variation. However, the allopregnanolone metabolite may persist somewhat longer, and inter-individual variation in 5-alpha-reductase activity creates meaningful differences in how sedating a given dose will be. Older patients and those on CYP3A4 inhibitors (such as ketoconazole or clarithromycin) may clear progesterone more slowly, raising the clinical concern for prolonged sedation after excess ingestion. The FDA label specifically flags CYP3A4 as the primary metabolic pathway (Prometrium FDA label).

Protein Binding and Volume of Distribution

Progesterone is approximately 96 to 99% bound to serum proteins, primarily albumin and corticosteroid-binding globulin. This high protein binding limits the utility of dialysis in overdose management, because very little free drug circulates in plasma. Activated charcoal within 1 to 2 hours of ingestion remains the most pharmacologically rational decontamination option if overdose is recognized early and the patient is fully alert.

Overdose Presentation: What to Expect Clinically

There is no large prospective case series of isolated oral micronized progesterone overdose, partly because the drug's toxicity profile makes intentional overdose an uncommon presentation and partly because most cases are managed with supportive care and not reported to registries. The clinical picture can be inferred from the drug's pharmacology and from case reports accessible via PubMed.

CNS and Respiratory Depression

The dominant feature of Prometrium excess is sedation, often described by patients as a "heavy" feeling that starts within 1 to 2 hours. At very high doses, sedation can progress to ataxia, slurred speech, and obtundation. Because allopregnanolone potentiates GABA-A in the brainstem as well as the cortex, respiratory depression is theoretically possible at sufficiently high concentrations, mirroring the pharmacology of benzodiazepine overdose. Reddy (2010) published a detailed review of allopregnanolone's GABAergic mechanism in Psychopharmacology, noting that CNS depression scales with plasma allopregnanolone level. In clinical practice, respiratory compromise from an isolated oral progesterone overdose has not been well-documented in adults at doses below several grams, but this does not mean the risk is zero, particularly in elderly patients or those co-ingesting alcohol or benzodiazepines.

Cardiovascular Effects

Progesterone has vasodilatory properties mediated partly through calcium channel inhibition and partly through nitric oxide pathways. Hypotension is possible after large doses, particularly in patients who are volume-depleted or co-ingesting antihypertensives. Cardiovascular effects of progesterone have been reviewed in a 2009 paper in the Journal of Cardiovascular Pharmacology. Clinically, vital-sign monitoring is warranted for any ingestion above 600 to 800 mg in a single dose.

Dizziness and Falls

Even at the 200 mg therapeutic dose, dizziness occurs in roughly 15 to 24% of women per trial data. After excess ingestion, vestibular symptoms and postural instability become a significant safety concern, especially in older adults. Falls represent the most practically dangerous consequence of accidental double-dosing in this population.

Specific Overdose Scenarios and Risk Stratification

Not all accidental excess doses carry the same risk. A practical way to think about exposure is by dose band.

Accidental Double Dose (200 to 400 mg When Standard Is 200 mg)

This is the most common scenario. A patient takes their nightly 200 mg capsule, forgets, and takes another one. Total ingestion: 400 mg. The FDA label already permits 400 mg per day in some protocols, so this dose band is within studied ranges. The patient should be advised to remain at home, not drive or operate machinery, stay near another adult if possible, and sleep it off. No emergency intervention is typically required if the patient is otherwise healthy and not co-ingesting CNS depressants.

Moderate Excess (400 to 800 mg Single Dose)

At this level, pronounced sedation and possible ataxia should be anticipated. If the patient is awake and presenting within 1 hour of ingestion, Poison Control guidance should be obtained. Activated charcoal (50 g in adults) may be appropriate if the patient is alert and able to protect their airway. The patient should not be left alone, and vital signs should be monitored if they present to an acute care facility.

High Dose Ingestion (Above 800 mg or Co-Ingestion With CNS Depressants)

Doses above 800 mg, or any dose taken alongside alcohol, benzodiazepines, opioids, or other GABA-A modulators, warrant emergency department evaluation. The additive GABAergic effect creates a meaningful risk of respiratory depression that exceeds the risk of either substance alone. An NIH review of drug interactions with neurosteroids confirms that co-administration with other CNS depressants amplifies sedation non-linearly.

Step-by-Step Management Protocol

The following protocol synthesizes FDA prescribing information, Poison Control guidance, and the pharmacological evidence base. It is intended for clinicians and should not replace real-time Poison Control consultation.

Step 1: Establish Time of Ingestion and Total Dose

Get the exact number of capsules taken, the time of ingestion, and whether the patient has eaten. Food triples bioavailability. A 400 mg dose taken with a full meal may produce greater CNS depression than a 600 mg dose taken fasting.

Step 2: Call Poison Control

In the United States, call 1-800-222-1222. Poison Control maintains real-time toxicology expertise and tracks outcomes. The American Association of Poison Control Centers logs all calls and can provide weight-based guidance not covered in the FDA label.

Step 3: Assess Airway, Breathing, and Circulation

Any patient with a Glasgow Coma Scale score below 14, respiratory rate below 12 breaths per minute, or oxygen saturation below 94% on room air should be transported to an emergency department immediately. These thresholds are consistent with standard ACLS-adjacent assessment principles. The NIH National Library of Medicine toxicology database outlines supportive care principles for sedative-type overdose.

Step 4: Decontamination (If Within 1 to 2 Hours and Patient Is Alert)

Activated charcoal 50 g orally may reduce absorption if given within 1 to 2 hours of ingestion. Do not give it to a patient who is already drowsy or unable to sit upright, because aspiration risk exceeds benefit. Gastric lavage is not recommended for isolated progesterone excess given the low toxicity ceiling and aspiration risk.

Step 5: Supportive Care

There is no antidote. Flumazenil, which reverses benzodiazepine-mediated GABA-A potentiation, does not reverse allopregnanolone-mediated GABA-A potentiation at the same receptor site. Research published in Neuropharmacology has confirmed that allopregnanolone and benzodiazepines bind distinct but overlapping sites, making flumazenil pharmacologically unreliable in this setting. Supportive care includes: IV access, cardiac monitoring, pulse oximetry, and aspiration precautions in the lateral decubitus position if the patient is sedated.

Step 6: Peanut Oil Allergy Consideration

Prometrium capsules contain peanut oil as the vehicle. In a patient with a known peanut allergy who has accidentally ingested a large number of capsules, watch for anaphylaxis signs (urticaria, angioedema, bronchospasm, hypotension) in addition to CNS depression. Epinephrine 0.3 mg intramuscularly is first-line treatment if anaphylaxis is suspected. The FDA label for Prometrium explicitly contraindicates the drug in patients with peanut allergy.

Special Populations With Elevated Risk

Older Adults

Age-related reductions in hepatic CYP3A4 activity slow progesterone clearance. Older adults have reduced GABA-A receptor plasticity, meaning they may be more sensitive to allopregnanolone at a given plasma concentration. The 2023 American Geriatrics Society Beers Criteria does not specifically list micronized progesterone, but it does flag sedating medications as high-risk for falls in older adults, a concern that becomes amplified after accidental double-dosing.

Patients With Hepatic Impairment

Because the liver performs the first-pass conversion of progesterone and subsequent metabolism of allopregnanolone, hepatic impairment prolongs and intensifies CNS effects after excess ingestion. The Prometrium prescribing information does not provide specific dose adjustments for hepatic impairment but warns that metabolism will be affected. Any patient with cirrhosis or active hepatitis who ingests excess Prometrium should be evaluated emergently.

Patients Co-Ingesting Alcohol

Alcohol and allopregnanolone are both positive allosteric modulators of GABA-A. Their interaction is supra-additive at the neurosteroid binding site. A patient who takes a double dose of Prometrium after drinking two glasses of wine faces greater respiratory depression risk than the arithmetic sum of either substance alone. Morrow et al. (2001) described this interaction in detail in the Journal of Pharmacology and Experimental Therapeutics.

Distinguishing Overdose From Expected Side Effects

The sedation that comes with a therapeutic 200 mg dose can itself alarm patients who are new to the drug. Knowing when sedation is expected versus concerning helps avoid unnecessary emergency visits and, equally, avoids dismissing a true overdose as normal side effects.

Normal After 200 mg at Bedtime

Drowsiness within 1 hour of taking the capsule, sleeping through the night more deeply than usual, mild next-morning grogginess. These effects typically diminish after the first 2 to 4 weeks of therapy as tolerance to the sedative component develops. A pharmacodynamic study by Simon et al. confirmed that CNS sedation peaks in week 1 and declines over subsequent weeks at constant dosing.

Abnormal at Any Dose

Slurred speech that persists more than 4 hours, inability to stand without assistance, oxygen saturation below 94%, confusion or agitation, or failure to fully wake 8 hours after ingestion. Any of these signs warrant medical evaluation regardless of the dose taken.

Drug Interactions That Amplify Overdose Risk

Several drug classes raise the effective pharmacodynamic or pharmacokinetic exposure to progesterone and its metabolites.

CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, grapefruit juice) increase plasma progesterone concentrations by slowing hepatic clearance. CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort) accelerate clearance and may reduce therapeutic efficacy. Other CNS depressants (benzodiazepines, opioids, gabapentinoids, alcohol) add to allopregnanolone's GABAergic effect. The FDA drug interaction table in the Prometrium label identifies CYP3A4 as the primary concern. Patients on these combinations need lower thresholds for emergency evaluation after excess ingestion.

When to Restart Therapy After an Accidental Excess Dose

Most patients can resume their normal nightly dose the following night after a single accidental double dose, once they are fully alert and their vital signs are normal. No specific wash-out period is required because the drug clears within 24 to 48 hours in most adults. A prescribing clinician should be notified so the incident can be documented and so pill-management strategies (blister packaging, medication reminder apps) can be discussed to prevent recurrence. The NAMS 2022 position statement recommends annual review of HRT regimens, which is an appropriate time to audit adherence barriers including accidental double-dosing.